Fujian Cosunter Pharmaceutical Co., Ltd. (SHE:300436)
China · Delayed Price · Currency is CNY 99.46
-1.19 (-1.18%)
Aug 14, 2026, 3:04 PM CST
SHE:300436 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 417.21 | 416.37 | 441.46 | 422.71 | 385.77 | 370.44 |
Revenue Growth | -0.43% | -5.68% | 4.43% | 9.58% | 4.14% | 0.53% |
Gross Profit Gross Profit Growth | 226.27 | 224.42 | 239.27 | 236.18 | 223.15 | 230.25 |
Operating Income Operating Income Growth | -133.38 | -132.06 | -124.74 | -212.07 | -224.96 | -81.06 |
Net Income Net Income Growth | -215.28 | -217.85 | -156.3 | -348.59 | -127.4 | -34.89 |
Earnings Per Share EPS Growth | -1.35 | -1.37 | -0.98 | -2.19 | -0.80 | -0.23 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Other Other Growth | 7.6 | 4.38 | 9.4 | 1.68 | 0.68 |
Direct Selling Direct Selling Growth | 291.97 | 288.86 | 282.57 | 251.74 | 244.84 |
Distribution Distribution Growth | 25.87 | 46.03 | 43.16 | 35.32 | 40 |
Government Procurement Government Procurement Growth | 90.93 | 102.19 | 87.59 | 92.7 | 84.93 |
Total Total Growth | 416.37 | 441.46 | 422.71 | 381.44 | 370.44 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 208.55 | 213.93 | 143.95 | 202.83 | 238.98 | 393.57 |
Total Debt Total Debt Growth | 486.96 | 455.97 | 442.56 | 459.27 | 311.55 | 187.33 |
Net Cash (Debt) Net Cash Growth | -278.41 | -242.03 | -298.6 | -256.44 | -72.57 | 206.24 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.75 | -1.52 | -1.87 | -1.61 | -0.46 | 1.38 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -42.59 | -35.05 | 20.71 | -174.6 | -119.68 | -17.76 |
Capital Expenditures CapEx Growth | -60.51 | -59.55 | -66.99 | -201.24 | -195.96 | -174.41 |
Free Cash Flow Free Cash Flow Growth | -103.1 | -94.6 | -46.28 | -375.83 | -315.64 | -192.17 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Gross Margin | 54.23% | 53.90% | 54.20% | 55.87% | 57.85% | 62.16% |
Operating Margin | -31.97% | -31.72% | -28.26% | -50.17% | -58.32% | -21.88% |
Pretax Margin | -54.94% | -55.06% | -37.24% | -70.50% | -42.36% | -12.33% |
Profit Margin | -51.60% | -52.32% | -35.41% | -82.47% | -33.03% | -9.42% |
FCF Margin | -24.71% | -22.72% | -10.48% | -88.91% | -81.82% | -51.88% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Forward PE | - | 46.43 | 46.43 | 46.43 | 46.43 | 46.43 |
PS Ratio | 37.97 | 34.10 | 11.79 | 9.66 | 16.17 | 20.59 |